BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32285316)

  • 1. Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer.
    Cho YH; Choi MG; Kim DH; Choi YJ; Kim SY; Sung KJ; Lee JC; Kim SY; Rho JK; Choi CM
    Target Oncol; 2020 Apr; 15(2):241-247. PubMed ID: 32285316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer.
    Choi MG; Kim YJ; Lee JC; Rho JK; Choi CM
    Thorac Cancer; 2020 Nov; 11(11):3337-3345. PubMed ID: 33017518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer.
    Lin M; Liang SZ; Shi J; Niu LZ; Chen JB; Zhang MJ; Xu KC
    Immunol Lett; 2017 Nov; 191():10-15. PubMed ID: 28916277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer.
    Lin M; Liang SZ; Wang XH; Liang YQ; Zhang MJ; Niu LZ; Chen JB; Li HB; Xu KC
    Immunol Res; 2017 Aug; 65(4):880-887. PubMed ID: 28508945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
    Mazzaschi G; Facchinetti F; Missale G; Canetti D; Madeddu D; Zecca A; Veneziani M; Gelsomino F; Goldoni M; Buti S; Bordi P; Aversa F; Ardizzoni A; Quaini F; Tiseo M
    Lung Cancer; 2019 Jan; 127():153-163. PubMed ID: 30642544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: retrospective clinical observation.
    Zhang G; Zhao H; Wu J; Li J; Xiang Y; Wang G; Wu L; Jiao S
    Int Immunopharmacol; 2014 Aug; 21(2):396-405. PubMed ID: 24881900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
    Pircher A; Gamerith G; Amann A; Reinold S; Popper H; Gächter A; Pall G; Wöll E; Jamnig H; Gastl G; Wolf AM; Hilbe W; Wolf D
    Lung Cancer; 2014 Jul; 85(1):81-7. PubMed ID: 24780112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
    Yang YJ; Park JC; Kim HK; Kang JH; Park SY
    Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
    Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
    Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study.
    Kokowski K; Stangl S; Seier S; Hildebrandt M; Vaupel P; Multhoff G
    Strahlenther Onkol; 2019 Apr; 195(4):352-361. PubMed ID: 30747241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials.
    Xiao Z; Wang CQ; Feng JH; Zhou MH; Wang YZ; Li NN; Sun YP; Liu SY; Yao XS; Li CW; Ma B; Ding J; Chen L
    Cytotherapy; 2019 Feb; 21(2):125-147. PubMed ID: 30554868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
    Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
    Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer.
    Russell É; Conroy MJ; Barr MP
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.
    Park HR; Ahn YO; Kim TM; Kim S; Kim S; Lee YS; Kim M; Keam B; Kim DW; Heo DS
    Cytotherapy; 2019 Jun; 21(6):603-611. PubMed ID: 31010733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.
    Kennedy PR; Vallera DA; Ettestad B; Hallstrom C; Kodal B; Todhunter DA; Bendzick L; Hinderlie P; Walker JT; Pulkrabek B; Pastan I; Kratzke RA; Fujioka N; Miller JS; Felices M
    Front Immunol; 2023; 14():1060905. PubMed ID: 36911670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-130a enhances the killing ability of natural killer cells against non-small cell lung cancer cells by targeting signal transducers and activators of transcription 3.
    Zhou X; Liu S; Liu J; Zhang Z; Mao X; Zhou H
    Biochem Biophys Res Commun; 2020 Mar; 523(2):481-486. PubMed ID: 31883616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased death and exhaustion of CD69
    Wang Y; Sun Z; Du X; Yu Q; Sun C; Huang J; Wang L
    PeerJ; 2023; 11():e15374. PubMed ID: 37180581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.